DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the EPIGRAL LIMITED (EPIGRAL) share price today?

EPIGRAL LIMITED (EPIGRAL) is trading at ₹1,051.9 on the NSE, down 1.45% on the day. Source: DocStoX.

What is the PE ratio of EPIGRAL LIMITED?

EPIGRAL LIMITED has a price-to-earnings (PE) ratio of 12.7 in the Chemicals sector.

What is the market capitalisation of EPIGRAL LIMITED?

EPIGRAL LIMITED has a market capitalisation of approximately ₹4,542 crore.

EPIGRAL LIMITED

EPIGRAL·NSE·Chemicals

₹1,051.90▼ -15.50 (-1.45%)

Chemicals · Specialty Chemicals

Revenue under pressure recently

Day₹1036.20

₹1069.90

52W₹804

₹211419%

Open

₹1067.00

High

₹1069.90

Low

₹1036.20

Prev Close

₹1067.40

Volume

30.4K

VWAP

₹1048.98

Snapshot

Key fundamentals

Market Cap

₹4,542 Cr

P/E Ratio

12.72Cheap

P/B Ratio

1.93

EPS

₹82.68

Book Value

₹514.92

ROE

14.94%Average

ROCE

25.00%Efficient

Dividend Yield

0.50%

Debt / Equity

0.26Low

Face Value

₹10.00

52W High

₹2114.00

52W Low

₹803.52

Sector

Chemicals

Industry

Specialty Chemicals

Expensive

Narrow moatVery High uncertainty

Fair value estimate

₹697

▼ 33.7%downside

Trading at ₹1,052 — 34% above our estimate

BearFair valueBull

₹572₹697₹979

/100

Business quality — Solid

Growth 0Profitability 58Efficiency 59Valuation 90

Plain English

Our view

Revenue under pressure recently
Low debt relative to equity
Revenue has been shrinking

Strengths

Low debt relative to equity
Capital is working hard (ROCE 25%)
Reasonably priced at 13× earnings
Promoters hold a controlling stake

Risks

Revenue has been shrinking

How we got there

Fair value methods

Residual income

15% ROE fading to 13% over ~10 yrs, on ₹515 book

₹572

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹979

Analyst target

No analyst coverage

—

Blended fair value₹697

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Capital is working hard (ROCE 25%)
Reasonably priced at 13× earnings
Promoters hold a controlling stake

Bear case

Revenue has been shrinking

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

12.7Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

14.9%Average

Above 15% is considered healthy for Indian equities

ROCE

25.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.26Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹4,542 Cr

P/B

1.93

EPS

₹82.68

Div Yield

0.50%

What changed

Recent changes

Foreign investors-0.5% stake last quarter
Domestic institutions+0.7% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 12.7×

Growth

Slow

+5% rev CAGR

Profitability

Healthy

14.9% ROE

Financial health

Rock solid

D/E 0.26

Momentum

N/A

No technicals

Today

Trading activity

Delivery %49.0%

Turnover₹319.34L Cr

Trades2,703

VWAP₹1048.98

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+4.9%

+25.0%

10Y

+20.4%

Profit

-2.0%

+26.9%

10Y

+17.4%

EPS

—

10Y

—

Profile

Pros

Company's median sales growth is 25.5% of last 10 years

Watch-outs

Cons

Tax rate seems low
Debtor days have increased from 42.4 to 60.2 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors sold 0.51 pts; domestic institutions added 0.66 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

69%

Promoter

Promoters

68.8%0.00

Public

24.6%-0.15

FII / FPI

1.0%-0.51

DII

5.6%+0.66

Quarterly trend

Ownership over time

Q1 FY27

Promoter68.83%

FII1.03%

DII5.56%

Public24.56%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals.[1]

EPIGRAL LIMITED valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

EPIGRAL LIMITED peers in Chemicals

Other Chemicals stocks on the NSE & BSE. See the full Chemicals sector list.

EPIGRAL LIMITED

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

EPIGRAL LIMITED valuation & research

EPIGRAL LIMITED peers in Chemicals

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions